Biotech company Crucell today announced that it has booked ‘positive results’ in the development of a vaccine against rabies. Crucell has tested the vaccine on volunteers in India and the US.
Investors reacted enthusiastically to the news and the company’s share price rose 5% on the Amsterdam exchange on Friday morning, reported ANP news service.
Crucell estimates that the market for the rabies vaccine is worth over €300m.
Around 10 million people worldwide are treated for rabies every year and up to 70,000 die from the disease, mainly in Asia, says Crucell.
Thank you for donating to DutchNews.nl.
We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.Make a donation